Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
Lymphoma, Non-Hodgkin
About this trial
This is an interventional treatment trial for Lymphoma, Non-Hodgkin focused on measuring Intermediate and High-Grade Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion: Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens. Exclusion: Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment Clinically significant pulmonary dysfunction. Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment). Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. History of autoimmune disease. History of positive serology for human immunodeficiency virus (HIV).
Sites / Locations
- ACRC/Arizona Clinical Research Center, Inc.
- Hoag Cancer Center
- UC Davis Cancer Center
- John Wayne Cancer Institute
- Stanford University Medical Center
- California Cancer Medical Center
- Georgetown University Medical Center, Lombardi Cancer Center
- Washington Cancer Institute
- Division of Hematology/Oncology, University of Miami School of Medicine
- Northwestern University, Feinberg School of Medicine
- Rush Cancer Institute
- Oncology Specialists, S.C.
- Cancer Care Center
- Consultants in Blood Disorders and Cancer
- Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology
- Kansas City Oncology and Hematology Group
- Arch Medical Group, LLC
- Dartmouth-Hitchcock-Medical Center
- Our Lady of Mercy Medical Center, Comprehensive Cancer Center
- Memorial Sloan Kettering Cancer Center
- East Carolina University School of Medicine/ Division of Hematology/Oncology
- Roger Maris Health System
- Gabrail Cancer Center
- Oncology Hematology Care Inc.
- The Cleveland Clinic Foundation
- Hematology /Oncology Consultants Inc.
- Oregon Heath and Science University
- University of Pennsylvania
- Cancer Centers of the Carolinas
- Germantown Cancer Center
- Vanderbilt University Medical Center
- Cancer Specialists of South Texas, P.A.
- Virginia Cancer Institute